Drug Interactions
Evaluation of drug-drug interaction risk is an important part of drug safety evaluation required by the drug regulatory authorities. Both FDA and EMA guidelines for drug-drug interaction studies suggest that investigational drugs should be tested for their potential to inhibit or induce metabolic enzymes and drug transporters that are associated with clinically relevant drug-drug interactions. Additionally, the role of individual enzymes and transporters in metabolism and disposition of the investigational drugs should be characterized, in order to understand the potential for drug-drug interactions due to inhibition or induction of mechanisms dictating its pharmacokinetics. Our services include enzyme phenotyping, clarifying the enzymes metabolizing the new chemical entity itself, and high-quality assays for inhibition and induction of CYP and UGT, as well as inhibition towards some less common metabolizing enzymes, such as FMO, MAO, CES, AOX and NAT.
